Principal Financial Group Inc. Grows Stake in Hims & Hers Health, Inc. $HIMS

Posted by Francis Steltz on Jul 21st, 2026

Principal Financial Group Inc. increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 97.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,282,266 shares of the company’s stock after acquiring an additional 632,282 shares during the quarter. Principal Financial Group Inc.’s holdings in Hims & Hers Health were worth $26,620,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in HIMS. Fifth Third Bancorp raised its holdings in shares of Hims & Hers Health by 3,584.8% in the 1st quarter. Fifth Third Bancorp now owns 82,171 shares of the company’s stock valued at $1,706,000 after acquiring an additional 79,941 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of Hims & Hers Health by 150.6% in the first quarter. Hsbc Holdings PLC now owns 84,159 shares of the company’s stock worth $1,741,000 after purchasing an additional 50,577 shares during the last quarter. Graetz Wealth LLC raised its stake in Hims & Hers Health by 156.0% in the first quarter. Graetz Wealth LLC now owns 15,891 shares of the company’s stock valued at $330,000 after purchasing an additional 9,683 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Hims & Hers Health by 3.1% during the first quarter. Oregon Public Employees Retirement Fund now owns 42,700 shares of the company’s stock valued at $886,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Abel Hall LLC purchased a new position in Hims & Hers Health in the 1st quarter worth approximately $290,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 0.5%

HIMS opened at $32.69 on Tuesday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The business has a 50 day simple moving average of $30.21 and a two-hundred day simple moving average of $26.34. The firm has a market capitalization of $7.57 billion, a price-to-earnings ratio of -363.18, a PEG ratio of 92.42 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 earnings per share. Analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 7,163 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the completion of the sale, the chief financial officer directly owned 284,321 shares of the company’s stock, valued at approximately $10,374,873.29. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the sale, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. The trade was a 3.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 83,126 shares of company stock valued at $2,711,339 over the last quarter. 11.76% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HIMS. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Bank of America raised their price target on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 9th. TD Cowen dropped their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $30.70.

Get Our Latest Research Report on Hims & Hers Health

About Hims & Hers Health

(Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.